Lauer Missouri Endowed Chair News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lauer missouri endowed chair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lauer Missouri Endowed Chair Today - Breaking & Trending Today

Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy

ACC late-breaking phase 3 data from EXPLORER-HCM trial on first-in-class cardiac myosin inhibitor ....

Carey Kimmelstiel , Jay Edelberg , Johna Spertus , University Of Missouri , Cardiomyopathy Development At Bristol Myers Squibb , Saint Luke Mid America Heart Institute , American College Of Cardiology , Bristol Myers Squibb , American College , Saint Luke , Mid America Heart Institute , Lauer Missouri Endowed Chair , Myers Squibb , Heart Failure , Cardiomyopathy Development , Bristol Myers , Hypertrophic Cardiomyopathy , Cardiac Myosin , Septal Ablation , Treat Hypertrophic Cardiomyopathy , ஜொன்னா ஸ்ப்பேர்த்துச் , பல்கலைக்கழகம் ஆஃப் மிச Ou ரி , துறவி லூக் நடுவில் அமெரிக்கா இதயம் நிறுவனம் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , அமெரிக்கன் கல்லூரி ,

Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiologys 70th Annual Scientific Session

Posted on
1113
Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70
th Annual Scientific Session (ACC.21), with simultaneous publication in
The Lancet. At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales. Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement (≥20 points) in the KCCQ OSS, compared to placebo, 36% [33/92] vs. 15% [13/88]. A change of at least 5 points is required to be considered clinically significant. These results were p ....

Johna Spertus , Bristol Myers Squibb , Susan Francis , American College Of Cardiology , Clinical Researchi Session , Exchange Commission , University Of Missouri , American College , Annual Scientific Session , Featured Clinical Researchi Session , Hot Topics Channel , Clinical Director , Outcomes Research , Saint Luke , Mid America Heart Institute , Lauer Missouri Endowed Chair , Hypertrophic Cardiomyopathy , Myers Squibb , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , ஜொன்னா ஸ்ப்பேர்த்துச் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , சூசன் பிரான்சிஸ் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் ,